Tag: KDC-MN-358

ACE-031 is a recombinant fusion protein composed of the extracellular domain of human activin receptor type IIB (ActRIIB) linked to the Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1), engineered to function as a circulating soluble decoy receptor that intercepts and neutralizes myostatin (growth and differentiation factor 8, GDF-8), activin A, activin B, GDF-11, and other transforming growth factor-beta (TGF-beta) superfamily ligands before they can engage their endogenous cell-surface receptors and transduce downstream Smad2/3-dependent signaling that constrains skeletal muscle growth. Developed by Acceleron Pharma (Cambridge, Massachusetts), ACE-031 was the first ActRIIB-Fc fusion protein to enter clinical trials in humans and the first systemic ligand trap approach to be tested in Duchenne muscular dystrophy (DMD), representing a pharmacological strategy that targets not a single ligand but the convergent signaling node through which multiple negative regulators of muscle mass operate.

The foundational preclinical work was established by Lee and McPherron (2001) and Lee et al. (2005), who demonstrated that a soluble form of ActRIIB produced dramatic skeletal muscle hypertrophy in wild-type mice and caused additive muscle gains even in myostatin-null animals, indicating that ligands beyond myostatin contribute to muscle mass regulation through the ActRIIB pathway. Acceleron subsequently developed ACE-031 as a pharmaceutical-grade recombinant protein and advanced it through preclinical studies in mice and non-human primates that demonstrated robust increases in lean body mass, thigh muscle volume, individual muscle fiber cross-sectional area, and ex vivo contractile force, with concurrent improvements in bone mineral density and favorable effects on fat metabolism. A Phase 1 single ascending-dose study in 48 healthy postmenopausal women (Attie et al., 2013, Muscle and Nerve) established linear pharmacokinetics with a mean terminal half-life of 10 to 15 days, demonstrated statistically significant increases of 3.3 percent in total body lean mass and 5.1 percent in thigh muscle volume at the 3 mg/kg dose after a single subcutaneous injection, and characterized a favorable acute safety profile.

The clinical development program advanced to a Phase 2 randomized, double-blind, placebo-controlled, ascending-dose trial in ambulatory, corticosteroid-treated boys with DMD (Campbell et al., 2017, Muscle and Nerve). The trial demonstrated trends toward increased lean body mass, increased bone mineral density, reduced fat mass, and maintenance of six-minute walk test distance in the ACE-031 groups compared to placebo, but was terminated after the second dosing cohort because of emergent vascular safety signals: epistaxis in 25 percent and mucocutaneous telangiectasias in approximately 21 percent of treated subjects. These events were subsequently attributed to the broad ligand-trapping profile of the unmodified ActRIIB extracellular domain, specifically the sequestration of bone morphogenetic proteins 9 and 10 (BMP9 and BMP10), which are critical regulators of endothelial cell homeostasis and vascular integrity. In May 2013, Acceleron Pharma and Shire PLC concluded their collaboration and announced they would not restart development of ACE-031.

The program’s discontinuation catalyzed two productive lines of successor development. Acceleron developed ACE-083, a follistatin-Fc fusion protein designed for local intramuscular injection that does not bind BMP9 or BMP10 and thus avoids the vascular signal. In parallel, the company developed luspatercept (ACE-536), a modified ActRIIB-Fc molecule with engineered ligand selectivity that avoids activin A and BMP trapping while retaining GDF-11 and GDF-8 neutralization, subsequently approved by the United States Food and Drug Administration for myelodysplastic syndrome-associated anemia and transfusion-dependent beta-thalassemia. ACE-031 itself is not approved by any regulatory authority for any indication. It remains available as a research-grade recombinant protein from chemical suppliers for in vitro and in vivo investigation of TGF-beta superfamily signaling, myostatin pathway biology, and muscle wasting pharmacology. Investigators should obtain analytical confirmation of identity, purity, and biological activity on every lot. This monograph documents the chemistry, mechanism of action, pharmacokinetics, preclinical pharmacology, clinical evidence, sourcing, handling, stack interactions, adverse-event profile, and comparative positioning of ACE-031 against five alternative myostatin/activin pathway inhibitors.